Adenocarcinoma on needle prostatic biopsies: Does reactive stroma predicts biochemical recurrence in patients following radical prostatectomy?


Department of Anatomic Pathology (AB, LM, LLLF, ASP, HAF, MMP); Medical Genetics/Biostatistics (LAM) and Urology (LOR, UF), School of Medical Sciences, State University of Campinas (Unicamp), Sao Paulo, Brazil

ABSTRACT

Objective: There is evidence that reactive stroma in different cancers may regulate tumor progression. The aim of this study is to establish any possible relation of reactive stroma grading on needle prostatic biopsies to biochemical recurrence.

Materials and Methods: The study group comprised 266 biopsies from consecutive patients submitted to radical prostatectomy. Reactive stroma was defined as stroma surrounding neoplastic tissue and graded as 0 (absent), 1 (slight), 2 (moderate), and 3 (intense) according to tumor stroma area relative to total tumor area.

Results: From the total of 266 needle prostatic biopsies, 143 (53.8%), 55 (20.7%), 54 (20.3%), and 14 (5.3%) showed grades 0, 1, 2, and 3, respectively. Increasing reactive stroma grade was significantly associated with clinical stage T2, higher preoperative PSA, higher biopsy and radical prostatectomy Gleason score, more extensive tumors in radical prostatectomy, and pathologic stage > T2. Only grade 3 was significantly associated with time and risk to biochemical recurrence. On multivariate analysis only preoperative PSA and 2 methods of biopsy tumor extent evaluation were independent predictors.

Conclusion: Increasing reactive stroma grade on biopsies is significantly associated with several clinicopathologic adverse findings, however, only grade 3 predicts time and risk to biochemical recurrence following radical prostatectomy on univariate but not on multivariate analysis. We have not been able to show that reactive stroma grade 3 on biopsies is an independent predictor of biochemical recurrence beyond that of preoperative PSA and other pathologic findings on biopsy.

INTRODUCTION

Several human cancers may induce a stromal reaction (desmoplasia) as a component of carcinoma progression. This has been described in breast and colon carcinoma (1,2). In cancers with stromal reaction, it seems that the response is similar, if not identical, to wound repair response (3). Prostate cancer may also be associated with wound repair type of reactive stroma composed of myofibroblasts and fibroblasts rather than normal prostate smooth muscle, which is displaced by the reactive stroma (4).

There is growing evidence that carcinogenesis is influenced and controlled by cellular
interactions derived from a complex relationship between stromal, epithelial and extracellular matrix components (4-15). The neoplastic stromal environment is different from the stroma of the normal tissue and is characterized by modified extracellular matrix composition, increased microvessel density, inflammatory cells and myofibroblasts (4,14,15).

A pioneer study by Ayala et al. (16) showed that the volume of reactive stroma in surgical specimens from patients submitted to radical prostatectomy was a significant predictor of biochemical recurrence. In a subsequent paper from the same group, Yanagisawa et al. (17) showed that intense reactive stroma on biopsies was an independent predictor of recurrence. The only other study dealing with the prognostic value of reactive stroma in prostate carcinoma is Tomas’ et al. (18). Using histochemistry and immunohistochemistry in radical prostatectomies, the authors found that on multivariate analysis only vimentin expression in reactive stroma was a significant predictor of biochemical recurrence.

Our study aims to establish the possible association of prostate cancer reactive stroma on needle biopsies and biochemical progression following radical prostatectomy.

**MATERIALS AND METHODS**

This retrospective study comprised 266 needle prostatic biopsies from 266 consecutive patients submitted to retropubic radical prostatectomy. No patient in this series received radiotherapy or androgen manipulation before or after surgery. The biopsy of the prostate was performed with transrectal ultrasound guidance and a spring-loaded 18-gauge needle instrument. Prostate was imaged in gray-scale mode and hypervascularity on color and power Doppler. The mean number and range of the cores obtained was 9 cores and 2-20 cores, respectively; and the mean and range of the length in mm of all cores 53 mm and 3-150 mm, respectively. All biopsies were analyzed by the same senior uropathologist (AB).

**Prostatic biopsies**

The analysis was done on slides stained with hematoxylin and eosin. Reactive stroma was defined as stroma surrounding the neoplastic tissue and that was not part of the normal preexisting host stroma. The scoring system was analyzed according to the stroma area relative to total tumor area and was based on the system proposed by Ayala et al. (16) and Yanagisawa et al. (17). Reactive stroma was graded as 0 (absent or up to 5% reactive stroma, Figures 1A and B), 1 (slight, 6% to 15% reactive stroma, Figure-1C), 2 (moderate, 16% to 50% reactive stroma, Figure-1D), and 3 (intense, > 50% reactive stroma, Figure-1E). In biopsies with cores showing different grades, the final grading was considered in the core with the most extensive carcinoma (index core). Reactive stroma is easily identified using hematoxylin and eosin stain and does not need special stains such as Masson’s trichrome.

Grading of reactive stroma was related to several clinicopathological variables: age, clinical stage, preoperative PSA, biopsy tumor extent using several methods of evaluation, radical prostatectomy tumor extent, biopsy and radical prostatectomy Gleason score, pathologic stage, and surgical margin status. For tumor grading was used the revised Gleason system according to the consensus conference of the International Society of Urological Pathology (19).

Tumor extent on needle biopsy was evaluated as number of needle biopsy cores with carcinoma (NC), number of needle biopsy cores with carcinoma divided by the total number of cores (%NC), total length of cancer in mm in all cores (mmAC), and total length of carcinoma in all cores divided by the total length of the cores (%mmAC). Linear extent of carcinoma in mm was measured using a single micrometer eyepiece with a linear array. In cases of discontinuous foci 1mm apart, the tumor was considered as continuous and the measure included 1mm. In discontinuous foci more than 1mm apart, the final extent was the sum of the measures.

**Surgical specimens**

The surgical specimens were step-sectioned at 3 to 5mm intervals and totally embedded in paraffin. A mean of 32 paraffin blocks were processed and 6µm sections from each block were stained with hematoxylin and eosin. Each transversal section of the prostate was subdivided into 2 anterolateral and 2 posterolateral quadrants. The basal and the apical margins were amputated and
Prostate cancer reactive stroma on biopsies was diagnosed when cancer was seen in adipose tissue and, in case of desmoplastic response, whenever a protuberance corresponding to extension of tumor into periprostatic tissue was observed. Seminal vesicle invasion occurred whenever there was involvement of the muscular coat. Tumor extent at radical prostatectomy was evaluated by a semiquantitative point-count method previously described (20).

After radical prostatectomy, serum PSA was drawn every 3 months during the first year, every 6 months during the second year, and annually thereafter. No patient had radiotherapy or androgen manipulation before or after surgery. Total serum PSA was measured utilizing previous validated Immulite® PSA kit. Biochemical recurrence following surgery was considered as PSA $\geq 0.2$ ng/mL according to recommendation of the American Urological Association (21). Patients without evidence of biochemical recurrence were censored at last follow-up. Institutional Committee of Ethics approved the study.

**Statistical analysis**

The data were analyzed using the Qui-square test for comparison of proportions, the Kruskal–Wallis test for comparison of means, the Kaplan–Meier product-limit analysis for the time to biochemical recurrence using the log-rank test for comparison between the groups, and a univariate and multivariate Cox stepwise logistic regression model to identify significant predictors of shorter time to biochemical recurrence. The P-values were two-sided at the significance level of $< 0.05$. All statistical analyses were performed using the commercially available PASW Statistics (SPSS) 18.0.

**RESULTS**

**Biopsies**

Table-1 shows the clinicopathologic characteristics of 266 patients undergoing radical prostatectomy according to biopsy reactive stroma grade. From the total of 266 needle prostatic biopsies, 143 (53.8%), 55 (20.7%), 54 (20.3%), and 14 (5.3%) biopsies showed absent (grade 0), slight (grade 1), moderate (grade 2), and intense (grade 3) reactive stroma, respectively.

sectioned parasagittally in a direction perpendicular to the initial transverse incision (cone method) obtaining 8 sections from each margin. Positive surgical margin was defined as cancer cells in contact with the inked specimen surface. Extraprostatic extension was diagnosed whenever cancer was seen in adipose tissue and, in case of desmoplastic response, whenever a protuberance corresponding to extension of tumor into periprostatic tissue was observed. Seminal vesicle invasion occurred whenever there was involvement of the muscular coat. Tumor extent at radical prostatectomy was evaluated by a semiquantitative point-count method previously described (20).
Table 1 - Clinicopathologic characteristics of 266 patients undergoing radical prostatectomy according to biopsy reactive stroma grade.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Grade 0</th>
<th>Grade 1</th>
<th>Grade 2</th>
<th>Grade 3</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of patients</td>
<td>143 (53.8%)</td>
<td>55 (20.7%)</td>
<td>54 (20.3%)</td>
<td>14 (5.3%)</td>
<td></td>
</tr>
<tr>
<td>Mean (SD; range)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age, years</td>
<td>64 (6.6;46-76)</td>
<td>62 (6.8;45-73)</td>
<td>63 (7.2;43-73)</td>
<td>65 (4.3;57-72)</td>
<td>0.69</td>
</tr>
<tr>
<td>Preoperative PSA (ng/mL)</td>
<td>8.6 (5.0;6-29.7)</td>
<td>9.5 (4.3;2.6-22.1)</td>
<td>11 (7.0;9-29-7)</td>
<td>18.1 (14.7;3.43-50)</td>
<td>&lt; 0.01</td>
</tr>
<tr>
<td>RP tumor extent (pos. points)</td>
<td>31.4 (30.9;1-192)</td>
<td>37.4 (30.4;1-147)</td>
<td>46.9 (45.3;5-222)</td>
<td>68.8 (71.2;20-225)</td>
<td>0.02</td>
</tr>
<tr>
<td>N (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical stage</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T1c</td>
<td>81 (58.7)</td>
<td>23 (44.2)</td>
<td>9 (19.6)</td>
<td>2 (16.7)</td>
<td>&lt; 0.01</td>
</tr>
<tr>
<td>T2</td>
<td>57 (41.3)</td>
<td>29 (55.8)</td>
<td>37 (80.4)</td>
<td>10 (83.3)</td>
<td>&lt; 0.01</td>
</tr>
<tr>
<td>RP Gleason score</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2-6</td>
<td>65 (45.5)</td>
<td>15 (27.3)</td>
<td>10 (19.2)</td>
<td>1 (7.1)</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>73 (51.0)</td>
<td>35 (63.6)</td>
<td>40 (76.9)</td>
<td>11 (78.6)</td>
<td></td>
</tr>
<tr>
<td>8-10</td>
<td>5 (3.5)</td>
<td>5 (9.1)</td>
<td>2 (3.8)</td>
<td>2 (14.3)</td>
<td></td>
</tr>
<tr>
<td>Biopsy Gleason score</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2-6</td>
<td>103 (72.0)</td>
<td>30 (54.5)</td>
<td>32 (59.3)</td>
<td>7 (50.0)</td>
<td>0.02</td>
</tr>
<tr>
<td>7</td>
<td>36 (25.2)</td>
<td>21 (38.2)</td>
<td>19 (35.2)</td>
<td>4 (28.6)</td>
<td></td>
</tr>
<tr>
<td>8-10</td>
<td>4 (2.8)</td>
<td>4 (7.3)</td>
<td>3 (5.6)</td>
<td>3 (21.4)</td>
<td></td>
</tr>
<tr>
<td>Pathologic stage</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T2</td>
<td>110 (76.9)</td>
<td>42 (76.4)</td>
<td>35 (64.8)</td>
<td>5 (35.7)</td>
<td>0.01</td>
</tr>
<tr>
<td>&gt; T2 (T3a/T3b)</td>
<td>33 (23.1)</td>
<td>13 (23.6)</td>
<td>19 (35.2)</td>
<td>9 (64.3)</td>
<td></td>
</tr>
<tr>
<td>Surgical margin status</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>86 (60.1)</td>
<td>29 (52.7)</td>
<td>28 (51.9)</td>
<td>5 (35.7)</td>
<td>0.27</td>
</tr>
<tr>
<td>Positive</td>
<td>57 (39.9)</td>
<td>26 (47.3)</td>
<td>26 (48.1)</td>
<td>9 (64.3)</td>
<td></td>
</tr>
</tbody>
</table>
Increasing reactive stroma grade was significantly associated with clinical stage T2, higher preoperative PSA, higher biopsy and radical prostatectomy Gleason score, more extensive tumors in radical prostatectomy, and pathologic stage > T2. There was no significant association with age and positive surgical margin.

Radical prostatectomies
From the total of 266 men following radical prostatectomy, 92 (34.6%) patients had biochemical recurrence at a mean, median and range follow-up of 19, 8, and 3-111 months; 162 (60.9%) censored men remained at risk at a mean, median and range follow-up of 59, 57, and 3-141 months, respectively; and, 12 (4.5%) men had no serum PSA data.

At 5 years following radical prostatectomy, 69%, 59%, 57%, and 39% from a total of 254 patients with grade 0, 1, 2, and 3 biopsy reactive stroma, respectively, were free of biochemical recurrence; 12/266 (4.5%) men had no serum PSA data. Only patients with needle biopsies showing grade 3 reactive stroma were significantly associated with shorter time to biochemical recurrence following surgery (log-rank, p < 0.01) (Figure-2).

Table-2 shows the Cox proportional hazard analysis of several clinicopathologic factors predicting time to biochemical recurrence following radical prostatectomy. On univariate analysis, preoperative PSA, all methods of biopsy tumor extent evaluation, and only needle biopsies with grade 3 reactive stroma were significant predictors of time to biochemical recurrence. On multivariate analysis, only preoperative PSA and 2 methods of biopsy tumor extent evaluation were independent predictors using two models of analysis.

DISCUSSION
We used the system proposed by Ayala et al. (16) and Yanagisawa et al. (17) for definition and scoring of reactive stroma. Reactive stroma was evaluated as stroma surrounding the neoplastic tissue and not part of the normal preexisting host stroma. The scoring system was established according to the stroma area relative to total tumor area. In biopsies with cores showing different grades, the final grading was considered in the core with the most extensive carcinoma (index core). Reactive stroma is easily identified using hematoxylin and eosin stain and does not need special stains such as Masson’s trichrome. No patient in this series received radiotherapy or androgen manipulation before or after surgery. This is important because both occurrences promote mesenchymal reaction that may interfere with the results.

All patients in our study had only one needle prostatic biopsy preceding surgery therefore there was no selection of biopsies. The mean number and range of the cores examined was 9 and 2-20, respectively and the mean and range of the length in mm of all cores 53 mm and 3-150 mm, respectively. Sampling of the biopsies is important for comparison of results.

According to intensity of reactive stroma, the frequency was 143/266 (53.8%), 55/266 (20.7%), 54 (20.3%), and 14/266 (5.3%) biopsies for grades 0, 1, 2, and 3, respectively. The frequency is higher in grade 0 and decreases to grade 3. On needle biopsies, Yanagisawa et al. (17) found a frequency of 1/224 (0.5%), 149/224 (66.5%), 59/224 (26.3%), and 15/224 (6.7%) biopsies for grades 0, 1, 2, and 3, respectively. In radical pros-
tatectomies, Ayala et al. (16) found a frequency of 34/545 (6.2%), 161/545 (29.5%), 306/545 (56.1%) , and 44/545 (8%) surgical specimens for grades 0, 1, 2, and 3, respectively.

The higher frequency of grade 0 (53.8%) in our study contrasts with the frequency of 0.5% and 6.2% of grade 0 in Yanagisawa’s et al. (17) and Ayala’s et al. (16) studies. Considering that the method of evaluation of reactive stroma is the same, it is difficult to explain this striking difference in frequency. Absence of reactive stroma is easily discernible as we can see in Figures 1A and B. One possible reason may be the additional use of trichrome staining to visualize reactive stroma in those prior studies. There is also a role of interobserver variability in interpretation of reactive stroma particularly when it is absent or lower grade. However, since distinction is more important for grade 3, which is relatively easier to identify, variation of interpretation in lower grades may not be significant.

Increasing reactive stroma grade was significantly associated with adverse clinicopathologic findings. Table-1 clearly shows the significant association with clinical stage T2, higher preoperative PSA, higher tumor extent in surgical specimen, higher Gleason score in biopsy and surgical specimen, and pathological stage >T2. There was no significant association with age and positive surgical margin. In Yanagisawa’s et al. (17) study,
reactive stroma grade in biopsies was significantly associated with clinical and pathological stage, surgical margin stage, and Gleason score on biopsy. No correlation was found with preoperative PSA and age.

The Kaplan-Meier product-limit analysis showed that only patients with reactive stroma grade 3 had significantly shorter time to biochemical recurrence (Figure-1). In Cox univariate analysis reactive stroma grade 3 is a significant predictor of shorter time to biochemical recurrence (Table-2). Yanagisawa et al. (17) found that patients with reactive stroma grade 0 and 3 had significantly shorter time to biochemical recurrence. A comment on this finding is the fact that they included in the same group 15 patients with reactive stroma grade 3 and only one patient with grade 0 in their series. It is not plausible any influence of this single patient with reactive stroma grade 0 in the analysis.

On multivariate analysis we used two models including only variables significantly predictive of time to biochemical recurrence on univariate analysis (Table-2). In model 1, only preoperative PSA and number of needle biopsy cores with carcinoma divided by the total number of cores (%NC) were significant; in model 2, only preoperative PSA and the total length of carcinoma in mm in all cores divided by the total length of the cores (%mmAC). This result is at odds with Yanagisawa’s et al. (17) study on biopsies. According to the authors reactive stroma grade 0 and 3 was an independent predictor of biochemical recurrence by Cox proportional hazard analysis. Their analyses were based on 205 patients with reactive stroma grade 1 and 2 vs. 16 patients with reactive stroma grade 0 and 3 (only one patient with grade 0).

In prostate cancer, the reactive stroma shows myofibroblasts that coexpress smooth-muscle marker (α-smooth-muscle actin) and mesenchymal marker (vimentin) and loss of late-stage smooth-muscle differentiation markers (desmin, calponin) (18). Based on these histological features, the only other study dealing with the prognostic value of reactive stroma in prostate carcinoma is Tomas’ et al. (18). The authors quantified histochemically and immunohistochemically the stromal reaction in radical prostatectomies. Patients with a higher vimentin or lower desmin expression had a shorter disease-free period and on multivariate analysis only vimentin expression was a significant predictor of biochemical recurrence. Further studies on needle prostatic biopsies may show utility of histochemistry and immunohistochemistry for the analysis of reactive stroma.

CONCLUSIONS

Increasing reactive stroma grade on needle prostatic biopsies is significantly associated with several clinicopathologic adverse findings. However, only grade 3 predicts time and risk to biochemical recurrence following radical prostatectomy on univariate analysis. On multivariate analysis we have not been able to show that reactive stroma grade 3 is an independent predictor of biochemical recurrence factoring in preoperative PSA and other pathologic findings on biopsy. An additional limitation of reactive stroma grade 3 as prognostic factor is the relatively rare occurrence of this finding (only 5.3% on needle biopsies).

ACKNOWLEDGMENTS

PSA = prostate specific antigen; SD = standard deviation; CI = confidence interval; NC = number of needle biopsy cores with carcinoma; %NC = percent of needle biopsy cores with carcinoma; mmAC = total length of cancer in mm in all cores; %mmAC = percent of total length of cancer in mm in all cores.

CONFLICT OF INTEREST

None declared.

REFERENCES


